NCT03893240 - Neutralizing Antibody Seroprevalence Study With a Retrospective Component in Participants With Late-Onset Pompe Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 12, 2019

Primary Completion Date

October 27, 2020

Study Completion Date

October 27, 2020

Conditions

Pompe DiseasePompe Disease (Late-onset)Glycogen Storage Disease Type 2LOPDLysosomal Storage DiseasesAcid Maltase Deficiency

Interventions

DIAGNOSTIC_TEST

Neutralizing Antibody to SPK-3006 capsid

Collected during a single study visit to establish the occurrence of neutralizing antibodies to SPK-3006 capsid in participants with LOPD on an enzyme replacement regimen.

Trial Locations (18)

10126

Azienda Ospedaliera Universitaria Citta della Salute e della Scienza di Torino, Torino

13385

Assistance Publique Hôpitaux de Marseille, Marseille

15213

University of Pittsburgh Medical Center, Pittsburgh

20122

Universita degli Studi di Milano - Clinica Oculistica I, Milan

27100

Fondazione Mondino Istituto Neurologico Nazionale a Carattere Scientifico, Pavia

55455

University of Minnesota Medical School, Minneapolis

56126

Azienda Ospedaliero Universitaria Pisana, Pisa

66160

University of Kansas Medical Center, Kansas City

80131

Università degli Studi di Napoli Federico II, Napoli

80333

Klinikum der Universität München, München

85013

Barrow Neurological Institute, Phoenix

92380

Hôpital Raymond-Poincaré, Garches

92868

University of California Irvine Health, Orange

97239

Oregon Health & Science University, Portland

98125

Università degli Studi di Messina, Messina

06001

CHU Nice, Nice

3015 CE

Erasmus University Medical Center, Rotterdam

M6 8HD

Salford Royal NHS Foundation Trust, Salford

All Listed Sponsors

lead

Spark Therapeutics, Inc.

INDUSTRY